Feb 3 (Reuters) - Sartorius Stedim Biotech SA STDM.PA:
SARTORIUS STEDIM BIOTECH ACHIEVES CONSIDERABLE PROFITABLE GROWTH IN 2025 AND MAINTAINS POSITIVE OUTLOOK
SALES REVENUE RISES TO 2,967 MILLION EUROS, UP 9.6% CONSTANT CURRENCIES
NET PROFIT AT 266 MILLION EUROS
FOR FISCAL YEAR 2026, SARTORIUS STEDIM BIOTECH EXPECTS SALES REVENUE TO INCREASE BY BETWEEN AROUND 6 AND 10 PERCENT IN CONSTANT CURRENCIES
OUTLOOK 2026: UNDERLYING EBITDA MARGIN SHOULD INCREASE TO SLIGHTLY ABOVE 31 PERCENT
DUE TO CONTINUED HIGH DYNAMICS AND VOLATILITY ACROSS LIFE SCIENCE INDUSTRY, FORECAST REMAINS SUBJECT TO GREATER UNCERTAINTY, WHICH IS REFLECTED IN CURRENT FORECAST RANGE
FY 2025 EPS EUR 2.73
FY EBITDA OF 914 MILLION EUROS
FY 2025 FREE CASH FLOW EUR 294.5 MILLION
Source text: ID:nEQ3trH5Pa
Further company coverage: STDM.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587696600;;))